Neuren partner Acadia bags FDA go-ahead for new DAYBUE STIX powder for Rett Syndrome
The new powder formulation gives children and adults living with Rett syndrome greater flexibility and choice in dose volume and taste
The new powder formulation gives children and adults living with Rett syndrome greater flexibility and choice in dose volume and taste
The drug is currently being evaluated in two fully recruited global Phase 3 studies for progressive and tophaceous gout, with results expected in 2026.
Clinical trial enrollment has long been a bottleneck in drug development
This is also an important milestone in our product strategy for our expansion into the larger Latin American market
Indoco received the Establishment Inspection Report from the USFDA for its API manufacturing facility
In her previous roles, Menon led significant digital transformation efforts, implementing predictive analytics, automation
WINREVAIR is currently the first and only activin signalling inhibitor approved for PAH across all 27 EU member states
The innovation -- UPM Circular Renewable Black -- is the world’s first bio-based, near-infrared (NIR) detectable, carbon-negative black
Subscribe To Our Newsletter & Stay Updated